DOCSLIB.ORG

Abstracts Presented at the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies June 4–8 2013, Toronto, Canada

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstracts Presented at the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies June 4–8 2013, Toronto, Canada Abstracts presented at the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies June 4–8 2013, Toronto, Canada cover page.indd 1 22/05/2013 11:10:37 cover page.indd 2 22/05/2013 11:10:37 ORI GAN ZING COMMITTEE Christoph Sarrazin, Chair J.W. Goethe-University Hospital, Germany Brendan Larder, Co-Chair RDI, UK Douglas Richman, Course Director University of California San Diego/VA Medical Center, USA Stephen Locarnini Victorian Infectious Diseases Reference Laboratory (VIDRL), Australia John Mellors University of Pittsburgh, USA SC IENTIFIC COMMITTEE Silvia Bertagnolio World Health Organization, Switzerland Bonaventura Clotet Fundacio IRSI Caixa, Spain John Coffin Tufts University, USA Abel De La Rosa Emory Institute for Drug Development & Drug Innovation Ventures at Emory University, USA Steven Deeks University of California, San Francisco, USA Matthias Götte McGill University, Canada Robert Grant Gladstone/UCSF, USA Huldrych Günthard University Hospital Zurich, Switzerland David Hall Boehringer Ingelheim Pharmaceuticals, USA George Hanna Bristol-Myers Squibb, USA Richard Harrigan BC Centre for Excellence in HIV/AIDS, Canada Daria Hazuda Merck Research Labs, USA Walid Heneine Centers for Disease Control and Prevention, USA Gillian Hunt NICD, South Africa Rolf Kaiser University of Cologne, Germany Tara Kieffer Vertex Pharmaceuticals, Inc., USA Daniel Kuritzkes Brigham and Women’s Hospital, USA Sharon Lewin The Alfred Hospital, Australia Susan Little University of California, San Diego, USA Frank Maldarelli NIH, USA Michael Miller Gilead Sciences, Inc., USA Veronica Miller Forum for Collaborative HIV Research, USA Sarah Palmer Westmead Millennium Institute and University of Sydney, Australia Jean-Michel Pawlotsky Henri Mondor Hospital, France Carlo-Federico Perno University of Rome Tor Vergata, Italy Christos Petropoulos Monogram Biosciences, a LabCorp Specialty Testing Group, USA Gastón Picchio Janssen R&D, USA Deenan Pillay University College London, UK Stuart Ray Johns Hopkins Medical Institutions, USA Jonathan Schapiro National Hemophilia Center, Israel Celia Schiffer University of Massachusetts Medical School, USA Raymond Schinazi Emory University/VA Medical Center, USA Robert Shafer Stanford University, USA David Standring Idenix Pharmaceuticals, Inc., USA Mark Wainberg McGill University AIDS Centre, Canada FACULTY Kristi Berger Boehringer Ingelheim Pharmaceuticals, Inc., USA Valerie Boltz National Cancer Institute, USA Christian Callebaut Gilead Sciences, Inc., USA Francesca Ceccherini-Silberstein University of Rome Tor Vergata, Italy Katherine Chan Gilead Sciences, Inc., USA Nicolas Chomont Vaccine & Gene Therapy Institute of Florida (VGTI-Florida), USA Suhman Chung NCI-Frederick, USA Alessandro Cozzi-Lepri University College London, UK Andrea De Luca Siena University Hospital, Italy Maryam Ehteshami Emory University, USA International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies vii Prelims 2013.indd 7 16/05/2013 11:18:56 Felix Feyertag University of Manchester, UK Anna Maria Geretti University of Liverpool, UK Charlotte Hedskog Gilead Sciences, Inc., USA Timothy Henrich Brigham and Women’s Hospital, Harvard Medical School, USA Edward Holmes The University of Sydney, Australia Jeffrey Johnson CDC, USA Mary Kearney HIV Drug Resistance Program, NCI, USA Brendan Larder RDI, UK Oliver Lenz Janssen Infectious Diseases, Belgium Jonathan Li Brigham and Women’s Hospital, Harvard Medical School, USA Dun Liang SAIC-Frederick, USA Malcolm Macartney Royal Free London NHS Foundation Trust, UK Frank Maldarelli NCI, USA Karin Metzner University of Zurich, Switzerland Donald Mosier The Scripps Research Institute, USA Danielle Porter Gilead Sciences, Inc., USA Peter Quashie McGill University AIDS Centre, McGill University, Canada Miguel Quiñones-Mateu UHCMC/CWRU, USA Stuart Ray Johns Hopkins Medical Institutions, USA Jacqueline Reeves Monogram Biosciences Inc., USA Rocio Sierra-Enguita Hospital Carlos III, Spain Cathia Soulie APHP Pitié Salpêtrière Hospital, France Djade Soumana University of Massachusetts Medical School, USA Valentina Svicher University of Rome Tor Vergata, Italy Luke Swenson BC Centre for Excellence in HIV/AIDS, Canada Mark Underwood GlaxoSmithKline, USA Cindy Vavro GlaxoSmithKline, USA Thor Wagner University of Washington, USA Carole Wallis Lancet Laboratories, South Africa Wan-Lin Yang University Hospital Zurich, Switzerland Tomokazu Yoshinaga Shionogi, Japan Jennifer Zerbato University of Pittsburgh, USA ORI GAN ZING SECRETARIAT Informed Horizons, LLC Telephone: +1 770 573 2627 Facsimile: +1 866 534 6438 Email: [email protected] Website: www.informedhorizons.com viii Programme & Abstracts Prelims 2013.indd 8 16/05/2013 11:18:56 CONTENTS Page Session Title and Presenting Author Abstract A1 PlENARY absTRACTS A3 Computational immunovirology of hepatitis C and implications P1 for resistance S Ray A4 Immunologic strategies to cure HIV infection P2 N Chomont A5 RNA virus evolution: a guide for the perplexed P3 EC Holmes A7 ORAL absTRACTS A9 Evolution of the HCV viral population from the one patient with 1 S282T detected at relapse after sofosbuvir monotherapy C Hedskog A10 Biochemical characterization of β-D-2′-C-methyl-2,6-diaminopurine- 2 ribonucleoside-5′-triphosphate as a potent inhibitor of hepatitis C virus (HCV) polymerase M Ehteshami A11 HCV GT2, GT3 and GT4 NS5B polymerases exhibit increased phenotypic 3 susceptibility to ribavirin and a nucleoside polymerase inhibitor JD Reeves A12 Early detection of NS3-resistance in HCV patients with advanced 4 disease treated with BOC/TVR-based therapy: analysis by population- and ultra-deep sequencing F Ceccherini-Silberstein A13 In vitro efficacy and resistance profiling of protease inhibitors 5 against a novel HCV genotype 3a replicon K Chan A14 Simeprevir in HCV genotype-1-infected patients: deep sequencing 6 analyses of the PILLAR and ASPIRE Phase IIb trials O Lenz A15 Structural and biochemical insights to asunaprevir’s drug resistance 7 profile D Soumana A16 Vir aemic control and viral coreceptor usage in two HIV-1-infected 8 homozygous CCR5 D32 individuals T Henrich International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies xv Prelims 2013.indd 15 16/05/2013 11:18:57 A17 High diversity in reverse transcriptase drug resistance mutations 9 relative to envelope variants in early-acute HIV transmission JA Johnson A18 Structural changes induced by the protease mutation V82I are 10 associated with a faster decline of CD4 cell count in drug-naive HIV-1-infected patients V Svicher A19 High level of HIV-1 drug resistance in South African adolescents 11 failing antiretroviral treatment CL Wallis A20 Accurate prediction of response to HIV therapy without a genotype: 12 a potential tool for therapy optimization in resource-limited settings BA Larder A21 Prevalence of transmitted drug resistance and relation to mean 13 population viral load of treatment failing patients: a 16-year analysis within the Swiss HIV Cohort Study (SHCS) W-L Yang A22 X4 tropic viruses are on the rise in recent HIV-1 seroconverters 14 R Sierra-Enguita A23 Multiple identical proviral sequences with identical integration sites 15 demonstrate proliferation of HIV-infected cells during suppressive antiretroviral treatment TA Wagner A24 Persistent elevation in HIV viraemia during cART with identical WT 16 sequences imply expansion of a clonal source F Maldarelli A25 Development of a primary cell model of HIV-1 latency in naive CD4+ 17 T-cells J Zerbato A26 Virus populations in plasma and tissues are well-mixed in RT-SHIV- 18 infected macaques MF Kearney A27 HIV-1 DNA decline during long-term first-line NNRTI-based ART 19 with consistent plasma HIV-1 RNA suppression below 50 copies/ml AM Geretti A28 Relationship and clinical significance of soluble markers of 20 inflammation and low-level viraemia in HIV-1 elite controllers JZ Li A29 Analysis and characterization of treatment-emergent resistance in 21 ART-experienced, integrase inhibitor-naive subjects with dolutegravir (DTG) versus raltegravir (RAL) in SAILING (ING111762) MR Underwood xvi Programme & Abstracts Prelims 2013.indd 16 16/05/2013 11:18:57 A30 Advanced mechanistic studies of GSK1265744, a new HIV integrase 22 inhibitor (INI) dosed by oral administration or long-acting parenteral injection T Yoshinaga A31 Antiviral activity of tenofovir alafenamide (TAF) against major 23 NRTI-resistant viruses: improvement over TDF/TFV is driven by higher TFV-DP loading in target cells C Callebaut A32 Low frequency of amino acid changes associated with resistance to 24 attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 B subtypes C Soulie A33 HIV-1 vpu and env mutations contribute to a novel mechanism of 25 resistance to CCR5 entry inhibitors DE Mosier A34 Population dynamics of R5-tropic HIV-1 associated with 26 maraviroc resistance F Feyertag A35 Examining the role of C-terminal domain of HIV-1 reverse 27 transcriptase p51 subunit in positioning and hydrolysis of RNA/DNA hybrids S Chung A36 Evidence for the importance of G118R in integrase inhibitor therapy 28 in different subtypes PK Quashie A37 Integrase genotypic and phenotypic predictors of antiviral response 29 to dolutegravir (DTG) in subjects with resistance to integrase inhibitors (INIs) CL Vavro A38 Primary and secondary analyses of emergent drug resistance through 30 week 48 from the STaR Study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF single-tablet
Load more

Recommended publications
  • CAPITULO 01.Indd
    DRUG RESISTANCE: 1. DEFINITIONS AND CONCEPTS • José Ramón Santos • Marc Noguera-Julian • Maria Casadellà • Josep Maria Llibre • Bonaventura Clotet • Roger Paredes 1.1. INTRODUCTION Definition Antiretroviral drug resistance is the ability of HIV to replicate in the presence of antiretroviral drug concentrations that suppress viral replication of non-resistant virus. Most antiretroviral drugs are competitive inhibitors, i.e. they inhibit a viral enzyme (protease, PR; reverse transcriptase, RT; integrase, IN) by competing with its natural substrate for attachment to the enzyme’s catalytic site. Resistance to competitive inhibitors is a function of viral susceptibility and the drug levels achieved in the target cells. Higher drug levels can suppress partially resistant viruses, with resistance occurring in a continuum. Viral susceptibility to competitive inhibitors is expressed as the drug concentration able to inhibit virus growth in vitro to 50% (50% inhibitory concentration, 1 IC50) or 90% (IC90), relative to a wildtype reference virus. The small-molecule CCR5 antagonists, are allosteric inhibitors of the human CCR5 transmembrane protein, one of the two co-receptors required for HIV entry into target cells. Due to their allosteric inhibition, decrease in viral susceptibility to CCR5 antagonists is reflected by progressive decreases in the percent of maximal inhibition rather than by shifts in IC50. Further increases in drug concentrations once drug resistance is established do not achieve further virological suppression. Pathogenesis HIV has a quasispecies distribution.1 Soon after infection with a relatively homogeneous viral population, viral replication ensues at an extraordinary rate: 109-12 new virions are generated every day. Because HIV’s RT lacks proofreading ability, 10-3 to 10-4 mutations (one or two per genome) are spontaneously generated per replication cycle.2, 3 Given HIV’s high replication rate, any single mutant and some dual mutants could be generated per day.
    [Show full text]
  • The Euresist Approach for Predicting Response to Anti HIV-1 Therapy!
    97! www.geno2pheno.org www.euresist.org The EuResist approach for predicting response to anti HIV-1 therapy! Andre Altmann1, Michal Rosen-Zvi2, Mattia Prosperi3, Ehud Aharoni2, Hani Neuvirth2, Eugen Schülter4, Joachim Büch1, Yardena Peres2, Francesca Incardona5, Anders Sönnerborg6, Rolf Kaiser4, Maurizio Zazzi7, Thomas Lengauer1 1 Max Planck Institute for Informatics, Saarbrücken, Germany; 2 IBM Research Laboratory in Haifa, Haifa, Israel; 3 University of Roma TRE, Rome, Italy; 4 University of Cologne, Cologne, Germany; 5 Informa srl, Rome, Italy; 6 Department of Medicine, Karolinksa Institute, Stockholm, Sweden; 7 University of Siena, Siena, Italy _____________________________________________________________ Background ____________________________________________________________ The aims of the EuResist project are integration of clinical and virologic data from a large cohort of patients and training of a data-driven therapy response prediction system for guiding treatment selection using these data. The EuResist Integrated Database (EIDB) currently comprises 18,467 patients, 22,006 sequences, 64,864 therapies, and 240,795 viral load (VL) measurements collected from Italy, Sweden, Germany, and Luxembourg. _______________________________________________________________ Methods______________________________________________________________ Therapy success (failure) is defined as a VL measurement below (above) 500 cp/ml at 8 [4-12] weeks after therapy start. Baseline VL and genotype must be obtained at most three months before therapy start to allow for inclusion in the training set. Using this Standard Datum definition we extracted 3,023 samples for training three different prediction engines. The engines were designed to work with viral genotype and intended regimen as the only information (minimal feature set) as well as with additional measurements (e.g. baseline VL) and information derived from previous treatments and genotypes (maximal feature set) to enhance prediction performance.
    [Show full text]
  • Fusion of Pure Data-Driven Approaches with Rules-Based Methods
    92! www.geno2pheno.org www.euresist.org Keeping models that predict response to antiretroviral therapy up-to- date: fusion of pure data-driven approaches with rules-based methods Andre Altmann1, Alexander Thielen1, Dineke Frentz2, Kristel Van Laethem3, Laura Bracciale4, Francesca Incardorna5, Anders Sönnerborg6, Maurizio Zazzi7, Rolf Kaiser8, Thomas Lengauer1 1 Max Planck Institute for Informatics, Saarbrücken, Germany; 2 Erasmus Medical Centre Rotterdam, Rotterdam, the Netherlands; 3 Katholieke Universiteit Leuven, Leuven, Belgium; 4 Catholic University of Rome, Rome, Italy; 5 Informa srl, Rome, Italy; 6 Department of Medicine, Karolinksa Institute, Stockholm, Sweden; 7 Department of Molecular Biology, University of Siena, Siena, Italy; 8 Institute of Virology, University of Cologne, Cologne, Germany ______________________________________________________________ Background ___________________________________________________________ Purely data-driven approaches predicting response to antiretroviral combination therapy (ART) are frequently criticized for not being easily applicable to novel compounds. This drawback originates from lack of treatments containing novel compounds in clinical databases that constitute the source of training data for statistical-learning methods. Here we present a method that integrates rules-based methods into data-driven approaches to overcome this limitation. __________________________________________________________ Material & Methods _______________________________________________________ Treatment Data Novel drug GSS (ndGSS) 4,538 treatment change episodes (TCEs) were extracted from the EuResist The 4,538 training TCEs did not contain novel drugs according to today's and Violab databases as training data for the approach. Response to ART was definition. However, for training of the new approach all drugs in a treatment dichotomized to success and failure based on the 8 (4-12) week follow-up viral that were approved by FDA at most 4 years prior to treatment start were treated load (VL), i.e.
    [Show full text]
  • Particularities of Visualisation of Medical and Wellness Data Through a Digital Patient Avatar
    ___________________________________________________PROCEEDING OF THE 14TH CONFERENCE OF FRUCT ASSOCIATION Particularities of Visualisation of Medical and Wellness Data through a Digital Patient Avatar Vadym Kramar, Markku Korhonen, Yury Sergeev Oulu University of Applied Sciences, School of Engineering Raahe, Finland {vadym.kramar, markku.korhonen, yury.sergeev}@oamk.fi Abstract—In this work particularities of visualisation of Descriptive – as providing access to any medical and medical and wellness data through a digital patient avatar are wellness data, including relevant to life-style; given from a standpoint of a proposed approach, under which Interpretive – as helping to be interpreted in order to data for a visualisation may be obtained from a variety of sources through defined interfaces, while end-user interfaces gain knowledge out of data; of distinct complexity and level of immersion into the model Integrative – as combining any possible data for may be exposed to different categories of users. A short retrieving decision-support required information; introduction of important medical data exchange standards, Predictive – as evaluating, anticipating, and predicting specifications and models is offered. A brief overview of the development of health aspects. projects relevant to a subject of this work is given. The proposed approach is presented along with examples of use- Taking into account a maturity of modern human to cases. computer interaction and user interface technologies, the key enablers for maturity of digital
    [Show full text]
  • EU-Funded FP6 Research Projects on Antimicrobial Drug Resistance
    EU-funded FP6 Research projects on Antimicrobial Drug Resistance Project information Interested in European research? Research*eu is our monthly magazine keeping you in touch with main developments (results, programmes, events, etc.). It is available in English, French, German and Spanish. A free sample copy or free subscription can be obtained from: European Commission Directorate-General for Research Communication Unit B-1049 Brussels Fax (32-2) 29-58220 E-mail: [email protected] Internet: http://ec.europa.eu/research/research-eu EUROPEAN COMMISSION Directorate-General for Research Directorate Health Unit Infectious Diseases http://ec.europa.eu/research/health/infectious-diseases/poverty-diseases/contact_en.html Contact: Rachida GHALOUCI European Commission Office CDMA 02/155 B-1049 Brussels Tel. (32-2) 29-64826 Fax (32-2) 29-94561 E-mail: [email protected] EUROPEAN COMMISSION EU-funded FP6 Research projects on Antimicrobial Drug Resistance Directorate-General for Research 2010 Cooperation/Health EN Europe Direct is a service to help you find answers to your questions about the European Union Freephone number(*): 00 800 6 7 8 9 10 11 (*)Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed LEGAL NOTICE Neither the European Commission nor any person acting on behalf of the Commis- sion is responsible for the use which might be made of the following information. The views expressed in this publication are the sole responsibility of the au- thor and do not necessarily reflect the views of the European Commission. More information on the European Union is available on the Internet (http://europa.eu).
    [Show full text]
  • Abstracts Presented at the International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge June 3–7 2014, Berlin, Germany
    Abstracts presented at the International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge June 3–7 2014, Berlin, Germany cover page.indd 1 09/06/2014 15:52:38 cover page.indd 2 09/06/2014 15:52:38 ORGANIZING COMMITTEE Carlo-Federico Perno, Guest Co-Chair University of Rome Tor Vergata, Italy Deenan Pillay, Guest Co-Chair University College London, UK Brendan Larder RDI, UK Stephen Locarnini Victorian Infectious Diseases Reference Laboratory (VIDRL), Doherty Institute, Australia John Mellors University of Pittsburgh, USA Douglas Richman, Course Director VA San Diego Healthcare System and University of California San Diego, USA Christoph Sarrazin J.W. Goethe-University Hospital, Germany SCIENTIFIC COMMITTEE Silvia Bertagnolio World Health Organization, Switzerland Bonaventura Clotet Fundacio IRSI Caixa, Spain John Coffin Tufts University, USA Abel De La Rosa Emory Institute for Drug Development & Drug Innovation Ventures at Emory University, USA Jim Demarest ViiV Healthcare LLC, USA Matthias Götte McGill University, Canada Robert Grant Gladstone/UCSF, USA Huldrych Günthard University Hospital Zurich, Switzerland David Hall Boehringer Ingelheim Pharmaceuticals, USA George Hanna Bristol-Myers Squibb, USA Richard Harrigan BC Centre for Excellence in HIV/AIDS, Canada Daria Hazuda Merck Research Labs, USA Walid Heneine Centers for Disease Control and Prevention, USA Gillian Hunt National Institute for Communicable Diseases (NICD), South Africa Rolf Kaiser University of Cologne, Germany Tara Kieffer Vertex Pharmaceuticals,
    [Show full text]
  • Prediction of Response to Antiretroviral Therapy by Human Experts and by the Euresist Data-Driven Expert System (The EVE Study)
    DOI: 10.1111/j.1468-1293.2010.00871.x r 2010 British HIV Association HIV Medicine (2010) ORIGINAL RESEARCH Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study) M Zazzi,1 R Kaiser,2 ASo¨nnerborg,3 D Struck,4 A Altmann,5 M Prosperi,6 M Rosen-Zvi,7 A Petroczi,8 Y Peres,9 E Schu¨lter,2 CA Boucher,10 F Brun-Vezinet,11 PR Harrigan,12 L Morris,13 M Obermeier,14 C-F Perno,15 P Phanuphak,16 D Pillay,17 RW Shafer,18 A-M Vandamme,19 K van Laethem,19 AMJ Wensing,20 T Lengauer5 and F Incardona21 1Department of Molecular Biology, University of Siena, Siena, Italy, 2Institute of Virology, University of Cologne, Cologne, Germany, 3Department of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden, 4CRP-Sante´, Laboratory of Retrovirology, Luxembourg, Luxembourg, 5Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbru¨cken, Germany, 6Clinic of Infectious Diseases, Catholic University of Rome, Rome, Italy, 7Machine Learning and Data Mining group, IBM Research Labs, Haifa, Israel, 8School of Life Sciences, Kingston University, Kingston upon Thames, UK, 9Knowledge Management Group, IBM Research Labs, Haifa, Israel, 10Department of Virology, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands, 11Laboratoire de Virologie, Hoˆpital Bichat Claude Bernard, Paris, France, 12BC Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada, 13AIDS Virus Research Unit, National Institute for Communicable
    [Show full text]
  • AI in HEALTHCARE WHITEPAPER BDVA Task Force 7 - Sub-Group Healthcare November 2020
    AI IN HEALTHCARE WHITEPAPER BDVA Task Force 7 - Sub-group Healthcare November 2020 1 TABLE OF CONTENTS Foreword ........................................................................................................................................... 4 Abstract ............................................................................................................................................ 5 Introduction .............................................................................................................................. 6 Importance of AI In Healthcare ............................................................................................... 8 2.1 Literature review ................................................................................................................ 8 2.2 Survey and workshop results ............................................................................................. 8 Key areas for AI in healthcare .............................................................................................. 10 3.1 Overview of key areas in health ....................................................................................... 10 3.2 Survey and Workshop results .......................................................................................... 12 Technical and research challenges ..................................................................................... 16 Non-technical challenges ....................................................................................................
    [Show full text]
  • Machine Learning Techniques for Predicting Complications And
    Machine learning techniques for predicting complications and evaluating drugs efficacy Three examples of real world evidence studies: combating AIDS, predicting diabetes complications and the epilepsy trial and error challenge Dr. Michal Rosen-Zvi Senior manager Analytics department IBM Research lab - Haifa, Israel Outline Data and needs in the medical world Machine Learning in a nutshell Three concrete examples – combating AIDS – predicting diabetes complications – the epilepsy trial and error challenge Wrap up 2 The Medical domain The first known medical record was developed by Hippocrates, in the fifth century B.C. He prescribed two goals: –A medical record should accurately reflect the course of disease –A medical record should indicate the probable cause of disease Hippocrates of Cos (460 BC – 370 BC) Father of western medicine “Medicine is a science of uncertainty and an art of probability.” “The greater the ignorance the greater the dogmatism. The truth of one age become the absurdities of the next, and the foolishness of yesterday become the wisdom of tomorrow.” Sir William Osler, (1849 – 1919), Father of modern medicine 3 Chronic diseases – prevalence and cost Diabetes 16 M $44-98B Cancer 15 M $37-107B $1.6T All other Congestive heart 5 M $20-40B $1.2T care failure $0.8T Respiratory 30 M $24-36B Treating disease chronic Hypertension 50 M $23-3B $0.4T disease HIV 0.7 M $20.5B* US healthcare spending 2002 Personalized healthcare requires Machine Learning capabilities for improving the care in various ways, including: Matching
    [Show full text]
  • A Vision for Predictive Health in Canada
    A Vision for Predictive Health in Canada Canada’s Big Data Consortium May 2018 We would like to thank the following organizations for their leadership and in-kind contributions to Canada’s Big Data Consortium, Canada’s Big Data Talent Gap Study, and to this paper, “A Vision for Predictive Health in Canada.” A Vision for Predictive Health_Print_v8.indd 1 2018-05-24 2:35 PM A Vision for Predictive Health_Print_v8.indd 2 2018-05-24 2:35 PM A Vision for Predictive Health in Canada Canada’s Big Data Consortium May 2018 A Vision for Predictive Health_Print_v8.indd 3 2018-05-24 2:35 PM Contents List of Figures 2.1.2 Factors for Quality, Physical, Mental, and 20 Emotional Health Executive Summary 04 2.2 Understanding Data Diversity 22 1 Introduction 05 2.2.1 Present and Emerging Data 22 1.1 Objectives and Organization of Paper 05 2.2.2 Standard Medical Terminology 23 1.2 Target Audience 06 2.2.3 Types of Data 24 1.3 Vision 08 2.2.4 Managing Data Flow and Use: Cloud 29 1.4 Evolving Healthcare System 10 Technology 1.4.1 Strengths in Technology, Big Data, Analytics, 12 2.2.5 Computational and Analytical Capabilities 31 Innovation 2.3 Basic Use of Electronic Health Records 32 1.5 Stakeholders in the Canadian Health System 13 2.3.1 Background: Electronic Medical Records and 32 1.5.1 Government 13 Electronic Health Records 1.5.2 Clinical Sphere 13 2.3.2 Data Integration 32 1.5.3 Academic Community 14 2.3.3 Long-term Preservation and Storage of Records 33 1.5.4 Research Community 15 2.3.4 Synchronization of Records: Access and Analytics 34 1.5.5 Health
    [Show full text]
  • Croi2020-Program-And-Information
    General Information CONTENTS Information General CROI FOUNDATION . 2 IAS–USA . 3 CONTINUING MEDICAL EDUCATION . 3 CROI 2020 PROGRAM COMMITTEE . 6 Scientific Program Committee . 6 Community Liaison Subcommittee . 8 EXTERNAL REVIEWERS . 9 SCHOLARSHIP AWARDEES . 11 Activities for New Investigator Awardees . 11 New Investigator Awardees . 11 International Investigator Awardees . 16 Community Educator Awardees . 16 CONFERENCE INFORMATION . 18 Overview . 18 Conference Support . 18 Conference Resources . .19. WiFi Access at the Conference . 19 Mobile App . 19 Poster Videos . 19 Website . 19 Webcasts . 19 USB Flashdrive . 20 Affiliated and Proximate Activities Policy . 20 Conference Badges . 20 Conference Etiquette . 20 VENUE Conference Services . 21 Meals . 22 Emergency Services . .22 Overflow Accommodations . 22 Americans With Disabilities Act . 22 Child Care . 22 CROI HOTELS . 23 ABSTRACT PROCESS . 25 Abstracts Related to Study Populations . 27 PRECONFERENCE SESSIONS . 28 SYMPOSIA, ORAL SESSIONS, AND THEMED DISCUSSIONS BY DAY . 34 POSTER SESSIONS BY DAY . 66 POSTER SESSIONS BY CATEGORY . 173. INDEX OF PRESENTING AUTHORS . .178 . CONFERENCE SCHEDULE . INSIDE BACK COVER CONVENTION CENTER FLOOR PLANS . BACK COVER Printed in the United States of America . © Copyright 2020 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-2-7 CROI 2020 1 General Information CROI FOUNDATION The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing,
    [Show full text]
  • European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update
    AIDS Rev. 2011;13:77-108 Anne-Mieke Vandamme, et al.: European HIV Drug Resistance Guidelines European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update Anne-Mieke Vandamme1,2, Ricardo J. Camacho2,3, Francesca Ceccherini-Silberstein4, Andrea de Luca5, Lucia Palmisano6, Dimitrios Paraskevis7, Roger Paredes8, Mario Poljak9, Jean-Claude Schmit10, Vincent Soriano11, Hauke Walter12, Anders Sönnerborg13 and the European HIV Drug Resistance Guidelines Panel 1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium; 2Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal; 3Laboratório de Biologia Molecular, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal; 4Department 5 of Experimental Medicine,University of Rome Tor Vergata, Rome, Italy; Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro © Permanyer Publications 2011 Cuore, Roma, and Second Division of Infectious Diseases, Siena University Hospital, Siena, Italy; 6Istituto Superiore di Sanità, Rome, Italy; 7National Retrovirus Reference Center, Department of Hygiene Epidemiology and Medical Statistics, Medical School University of Athens, Athens, Greece; 8 HIV Unit & IrsiCaixa AIDS Research Institute, Hospital Universitàri Germans Trias i Pujol, Badalona, Spain; 9Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; 10National Service of Infectious Diseases, Retrovirology Laboratory Luxembourg, Centre Hospitalier de
    [Show full text]